HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Robert L Coleman Selected Research

niraparib

3/2022Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer.
10/2020Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
1/2020Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review.
1/2020Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors.
11/2018Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Robert L Coleman Research Topics

Disease

165Ovarian Neoplasms (Ovarian Cancer)
12/2022 - 01/2002
163Neoplasms (Cancer)
01/2022 - 01/2002
65Carcinoma (Carcinomatosis)
04/2022 - 01/2002
40Ovarian Epithelial Carcinoma
11/2021 - 01/2002
33Endometrial Neoplasms (Endometrial Cancer)
04/2022 - 01/2007
20Uterine Cervical Neoplasms (Cancer of the Cervix)
01/2022 - 02/2002
16Disease Progression
01/2021 - 07/2008
11Neoplasm Metastasis (Metastasis)
01/2021 - 12/2006
9Neutropenia
12/2022 - 04/2006
9Anemia
12/2022 - 12/2010
9Fatigue
01/2022 - 01/2008
8Adenocarcinoma
01/2022 - 03/2004
8Fallopian Tube Neoplasms
12/2021 - 12/2006
7Nausea
01/2022 - 01/2008
7Uterine Neoplasms (Uterine Cancer)
10/2021 - 05/2009
6Hypertension (High Blood Pressure)
01/2022 - 11/2011
6Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2020 - 03/2002
5Breast Neoplasms (Breast Cancer)
06/2020 - 03/2009
5Hypoxia (Hypoxemia)
02/2018 - 11/2011
4Sarcoma (Soft Tissue Sarcoma)
01/2021 - 01/2020
4Vulvar Neoplasms (Vulvar Cancer)
04/2020 - 11/2012
4Ascites
10/2016 - 01/2011
4Pain (Aches)
07/2015 - 03/2002
3Exanthema (Rash)
01/2022 - 04/2006
3Vomiting
01/2021 - 01/2008
3Granulosa Cell Tumor
04/2020 - 09/2009
3Carcinosarcoma
01/2020 - 04/2011
3Adenosquamous Carcinoma
01/2020 - 12/2007
3Thrombocytopenia (Thrombopenia)
12/2019 - 05/2011

Drug/Important Bio-Agent (IBA)

64PlatinumIBA
12/2022 - 01/2002
35Paclitaxel (Taxol)FDA LinkGeneric
01/2022 - 01/2002
32Poly(ADP-ribose) Polymerase InhibitorsIBA
03/2022 - 06/2015
27Biomarkers (Surrogate Marker)IBA
01/2022 - 03/2004
26Bevacizumab (Avastin)FDA Link
05/2022 - 12/2007
22rucaparibIBA
12/2022 - 06/2016
22Carboplatin (JM8)FDA LinkGeneric
01/2022 - 01/2002
22Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2021 - 08/2006
18Pharmaceutical PreparationsIBA
12/2021 - 04/2006
17taxaneIBA
11/2017 - 01/2002
16Docetaxel (Taxotere)FDA Link
01/2016 - 08/2006
15Biological ProductsIBA
01/2021 - 12/2007
14liposomal doxorubicin (Doxil)FDA Link
11/2021 - 08/2004
13Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
03/2022 - 07/2013
13Topotecan (Hycamtin)FDA LinkGeneric
11/2020 - 01/2002
12Small Interfering RNA (siRNA)IBA
01/2022 - 08/2006
11Proteins (Proteins, Gene)FDA Link
01/2020 - 07/2008
10olaparibIBA
03/2022 - 11/2018
81-dodecylpyridoxal (PLD)IBA
11/2021 - 10/2006
7Monoclonal AntibodiesIBA
12/2021 - 09/2009
7Progesterone Receptors (Progesterone Receptor)IBA
04/2020 - 06/2009
7Cisplatin (Platino)FDA LinkGeneric
01/2020 - 01/2002
6Poly Adenosine Diphosphate RiboseIBA
05/2022 - 01/2020
6Estrogen ReceptorsIBA
11/2020 - 07/2008
5niraparibIBA
03/2022 - 11/2018
5EverolimusFDA Link
01/2022 - 12/2010
5trametinibIBA
01/2022 - 01/2015
5Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2022 - 07/2015
5Immunoconjugates (Immunoconjugate)IBA
01/2022 - 09/2009
5Letrozole (Femara)FDA LinkGeneric
01/2022 - 07/2008
5veliparibIBA
01/2022 - 06/2015
5ErbB Receptors (EGF Receptor)IBA
11/2020 - 01/2007
5Angiogenesis InhibitorsIBA
10/2020 - 12/2009
5Taxoids (Taxanes)IBA
01/2020 - 08/2006
5Focal Adhesion Protein-Tyrosine KinasesIBA
05/2019 - 08/2006
5GemcitabineFDA Link
01/2017 - 03/2007
5afliberceptIBA
01/2016 - 04/2008
5LigandsIBA
01/2016 - 02/2007
5Folic Acid (Vitamin M)FDA LinkGeneric
03/2015 - 06/2013
5Proliferating Cell Nuclear Antigen (PCNA)IBA
11/2011 - 09/2006
51,2-oleoylphosphatidylcholine (DOPC)IBA
11/2011 - 08/2006
4Peptides (Polypeptides)IBA
01/2021 - 04/2014
4DNA (Deoxyribonucleic Acid)IBA
10/2020 - 12/2008
4Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
06/2016 - 01/2007
4farletuzumabIBA
03/2015 - 03/2010
4Folate Receptor 1IBA
01/2015 - 03/2010
3MK 2206IBA
04/2022 - 01/2020
3tisotumab vedotinIBA
01/2022 - 01/2020
3FANG vaccineIBA
12/2021 - 12/2020
3Dasatinib (BMS 354825)FDA Link
10/2021 - 04/2014
3Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
01/2021 - 01/2014
3TrabectedinIBA
01/2021 - 01/2020
3Hemoglobins (Hemoglobin)IBA
01/2021 - 02/2013
3Tyrosine Kinase InhibitorsIBA
11/2020 - 07/2014
3Hormones (Hormone)IBA
04/2020 - 06/2009
3Liposomes (Liposome)IBA
05/2019 - 08/2006
3Adrenergic Agents (Adrenergic Drugs)IBA
01/2019 - 08/2006

Therapy/Procedure

137Therapeutics
05/2022 - 01/2002
75Drug Therapy (Chemotherapy)
12/2022 - 01/2002
14Hysterectomy
10/2021 - 02/2002
13Neoadjuvant Therapy
01/2022 - 03/2008
12Lymph Node Excision (Lymph Node Dissection)
10/2021 - 02/2002
8Cytoreduction Surgical Procedures
12/2021 - 10/2010
8Immunotherapy
12/2021 - 01/2015
5Combination Drug Therapy (Combination Chemotherapy)
04/2011 - 03/2007
4Salpingo-oophorectomy
07/2020 - 03/2009
4Laparotomy
01/2020 - 01/2007
4Minimally Invasive Surgical Procedures
01/2020 - 10/2010
4Drug Tapering
01/2019 - 04/2006
4Radiotherapy
12/2010 - 01/2005
3Aftercare (After-Treatment)
11/2020 - 01/2007